21st.BIO specializes in delivering precision fermentation technology to accelerate the production of sustainable proteins and peptides. Their platform bridges the gap between lab innovation and industrial-scale manufacturing, leveraging expertise from Novo Nordisk and Novonesis. They offer shared development programs for nature-identical molecules and bespoke projects for exclusive protein assets, enabling faster, lower-risk market entry for partners.
Preferred startup development maturity for initial funding deployment.
Precision fermentation technology platform for proteins and peptides, enabling scalable biomanufacturing
Core thematic spaces, technologies, and target market segments of interest.
Standard financial allocation per investment round.
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...